B
B

Financials • BioAtla

BCAB

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
0
-95
-12
L
L
211
L
-245
-
-87
-1
70
-88
0
0
-
-
12/2022
0
-107
-123
0%
L
180
L
-216
-
-105
-0
61
-105
-1
0
-
-
12/2023
0
-128
-123
0%
L
71
L
-111
-
-118
-0
0
-118
-0
0
-
-
12/2024
11
-73
-12
L
L
14
L
-49
-
-81
0
10
-81
-0
0
-
-
12/2025
2
-59
-12
L
L
-36
L
-7
-
-54
0
6
-54
-0
0
-
-

To see all financials—including updated, you must be Premium.